The 80th Annual Meeting of the Japanese Society of Hematology

Session information

Oral Session

Oral Session 2-9A MM: Global clinical trials

Sat. Oct 13, 2018 9:00 AM - 10:00 AM No.9 (Osaka International Convention Center, 10F 1008)

Chair: Hiroshi Handa (Gunma University Graduate School of Medicine Department of Hematology, Japan)

【E】

Paul Richardson1, Albert Oriol2, Meral Beksac3, Anna Marina Liberati4, Monica Galli5, Fredrik Schjesvold6, Jindriska Lindsay7, Katja Weisel8, Darrell White9, Thierry Facon10, Jesus San Miguel11, Kazutaka Sunami12, Peter O Gorman13, Pieter Sonneveld14, Pawel Robak15, Sergey Semochkin16, Steve Schey17, Xin Yu18, Thomas Doerr18, Amine Bensmaine18, Tsvetan Biyukov19, Sanae Sakurai20, Mohamed Zaki18, Kenneth Anderson1, Meletios Dimopoulos21 (1.Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America, 2.Institut Catala d Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain, 3.Ankara University, Cebeci Yerleskesi, Dikimevi, Republic of Turkey, 4.University of Perugia, Terni, Italian Republic, 5.A.O. Papa Giovanni XXIII, U.O. di Ematologia, Bergamo, Italian Republic, 6.Oslo University Hospital, Oslo, Kingdom of Norway, 7.East Kent Hospitals University NHS Foundation Trust, Canterbury, United Kingdom of Great Britain and Northern Ireland, 8.University Hospital of Tuebingen, Tuebingen, Federal Republic of Germany, 9.Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, Canada, 10.Service des Maladies du Sang, Hopital Claude Huriez, Lille, French Republic, 11.Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain, 12.National Hospital Organization Okayama Medical Center, Okayama, Japan, 13.Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland, 14.Erasmus MC Cancer Institute, Rotterdam, Kingdom of the Netherlands, 15.Medical University of Lodz, Lodz, Republic of Poland, 16.Pirogov Russian National Research Medical University, Moscow, Russian Federation, 17.Department of Hematology, King's College London, London, United Kingdom of Great Britain and Northern Ireland, 18.Celgene Corporation, Summit, United States of America, 19.Celgene International Sarl, Boudry, Swiss Confederation, 20.Celgene K.K., Tokyo, Japan, 21National and Kapodistrian University of Athens, Athens, Republic of Cyprus)

Andrew Spencer1, Vania Hungria2, Roman Hajek3, Katja Weisel4, Francesca Gay5, Meral Beksac6, Piruntha Thiyagarajah7, Himal Amin8, Xiang Qin9, Jordan M. Schecter8, Pieter Sonneveld10 (1.Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Clayton, Australia, 2.Irmandade Da Santa Casa De Misericordia De Sao Paulo, Sao Paulo, Federative Republic of Brazil, 3.Fakultni nemocnice Ostrava, Ostrava-Poruba-Poruba, Czech Republic, 4.Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tubingen, Federal Republic of Germany, 5.Division of Hematology, University of Torino, A.O.U. San Giovanni Battista, Torino, Italian Republic, 6.Ankara University, Department of Hematology, Ankara, Republic of Turkey, 7.Janssen Research & Development, LLC, High Wycombe, United Kingdom of Great Britain and Northern Ireland, 8.Janssen Research & Development, LLC, Raritan, United States of America, 9.Janssen Research & Development, LLC, Spring House, United States of America, 10.Department of Hematology, Erasmus MC, Rotterdam, Kingdom of the Netherlands)

Camille V. Edwards1, Divaya Bhutani2, Markus Mapara2, Jai Radhakrishnan3, Sofia Shames4, Mathew S. Maurer4, Siyang Leng2, Alan Solomon5, Suzanne Lentzsch2, Andrew Eisenberger2 (1.Department of Hematology and Oncology, Boston Medical Center, Boston, United States of America, 2.Division of Hematology and Oncology, Columbia University Medical Center, New York, United States of America, 3.Division of Nephrology, Columbia University Medical Center, New York, United States of America, 4.Division of Cardiology, Columbia University Medical Center, New York, United States of America, 5.Graduate School of Medicine, University of Tennessee, Knoxville, United States of America)

Kenshi Suzuki1, Michele Cavo2, Meletios A. Dimopoulos3, Jesus San-Miguel4, Andrzej Jakubowiak5, Sung-Soo Yoon6, Mark Cook7, Mario Boccadoro8, P. Joy Ho9, Ludek Pour10, Stefan Knop11, Chantal Doyen12, Andre Crepaldi13, Tamas Masszi14, Joan Blade15, Jianping Wang16, Susan Wroblewski17, William Deraedt18, Ming Qi17, Maria-Victoria Mateos19 (1.Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan, 2.Seragnoli Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italian Republic, 3.National and Kapodistrian University of Athens, Athens, Hellenic Republic, 4.Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain, 5.University of Chicago Medical Center, Chicago, United States of America, 6.Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea, 7.University Hospitals Birmingham NHS Trust, Birmingham, United Kingdom of Great Britain and Northern Ireland, 8.Myeloma Unit, Division of Hematology, University of Torino, Torino, Italian Republic, 9.Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia, 10.University Hospital Brno, Brno, Czech Republic, 11.Wuerzburg University Medical Center, Wuerzburg, Federal Republic of Germany, 12.Universite catholique de Louvain (UcL) CHU UCL Namur, Yvoir, Kingdom of Belgium, 13.Clinica de Tratamento E, Cuiaba, Federative Republic of Brazil, 14.Department of Haematology and Stem Cell Transplantation, St Laszlo Hospital, 3rd Department of Internal Medicine, Semmelweis University, Budapest, Republic of Hungary, 15.Servei d'Hematologia, Hospital Clinic de Barcelona, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain, 16.Janssen Research & Development, Raritan, United States of America, 17.Janssen Research & Development, Spring House, United States of America, 18.Janssen Research & Development, Beerse, Kingdom of Belgium, 19.University Hospital of Salamanca/IBSAL, Salamanca, Spain)

Annette Lam1, Thierry Facon2, Meletios A. Dimopoulos3, Maria-Victoria Mateos4, Michele Cavo5, Bart Heeg6, Sophie van Beekhuizen6, Marta Pisini7, Sandhya Nair8, Mary Slavcev1, Jesus San-Miguel9 (1.Janssen Global Services, Raritan, United States of America, 2.Hopital Claude Huriez, CHRU Lille, Lille, France Metropolitan, 3.National and Kapodistrian University of Athens, Athens, Hellenic Republic, 4.University Hospital of Salamanca/IBSAL, Salamanca, Spain, 5.“Seragnoli” Institute of Hematology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italian Republic, 6.Ingress Health, Rotterdam, Kingdom of the Netherlands, 7.Janssen EMEA, Kingdom of Belgium, 8.Janssen Research and Development, Beerse, Kingdom of Belgium, 9.Clinica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain)